Genmab A/S (NASDAQ:GMAB) Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC lowered its position in Genmab A/S (NASDAQ:GMAB) by 2.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 227,959 shares of the company’s stock after selling 6,263 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Genmab A/S were worth $5,558,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in shares of Genmab A/S by 360.5% in the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after purchasing an additional 23,094 shares during the last quarter. Capital International Investors lifted its stake in Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after buying an additional 315,355 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after buying an additional 45,376 shares in the last quarter. Choreo LLC acquired a new position in shares of Genmab A/S in the second quarter valued at approximately $776,000. Finally, Renaissance Technologies LLC lifted its position in Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 0.1 %

GMAB stock opened at $22.75 on Wednesday. Genmab A/S has a twelve month low of $22.18 and a twelve month high of $32.89. The company has a market cap of $15.06 billion, a P/E ratio of 18.80, a PEG ratio of 0.67 and a beta of 0.99. The business has a fifty day moving average of $24.68 and a 200-day moving average of $26.50.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million. As a group, equities research analysts anticipate that Genmab A/S will post 1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Truist Financial cut their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.